Morgan Stanley
ELDN icon

Morgan Stanley’s Eledon Pharmaceuticals ELDN Stock Holding History

Morgan Stanley’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$447K Sell
145,158
-95,387
-40% -$225K ﹤0.01% 5537
2025
Q4 		$363K Buy
240,545
+1,386
+0.6% +$3.29K ﹤0.01% 5675
2025
Q3 		$619K Sell
239,159
-106,470
-31% -$311K ﹤0.01% 5417
2025
Q2 		$937K Buy
345,629
+123,672
+56% +$371K ﹤0.01% 5128
2025
Q1 		$752K Buy
221,957
+47,451
+27% +$195K ﹤0.01% 5137
2024
Q4 		$719K Buy
174,506
+91,035
+109% +$359K ﹤0.01% 5256
2024
Q3 		$208K Buy
83,471
+81,316
+3,773% +$218K ﹤0.01% 5742
2024
Q2 		$5.69K Hold
2,155
– – ﹤0.01% 6818
2024
Q1 		$4.44K Sell
2,155
-2,155
-50% -$3.85K ﹤0.01% 6922
2023
Q4 		$7.76K Buy
4,310
+2,155
+100% +$3K ﹤0.01% 6893
2023
Q3 		$2.95K Hold
2,155
– – ﹤0.01% 7039
2023
Q2 		$2.95K Buy
+2,155
New +$4.49K ﹤0.01% 7109
2023
Q1 		– Sell
-1
Closed -$2 – 7747
2022
Q4 		$2 Sell
1
-1,132
-100% -$2.8K ﹤0.01% 7854
2022
Q3 		$3K Sell
1,133
-899
-44% -$2.86K ﹤0.01% 7376
2022
Q2 		$5K Buy
2,032
+278
+16% +$848 ﹤0.01% 7395
2022
Q1 		$7K Sell
1,754
-7,017
-80% -$27.2K ﹤0.01% 7497
2021
Q4 		$39K Sell
8,771
-100,685
-92% -$509K ﹤0.01% 6921
2021
Q3 		$677K Sell
109,456
-741,548
-87% -$5.18M ﹤0.01% 5314
2021
Q2 		$6.73M Buy
851,004
+839,403
+7,236% +$7.92M ﹤0.01% 3454
2021
Q1 		$124K Sell
11,601
-32,777
-74% -$495K ﹤0.01% 5897
2020
Q4 		$683K Buy
+44,378
New +$846K ﹤0.01% 4885
2020
Q3 		– Sell
-2
Closed – – 6754
2020
Q2 		$0 Buy
+2
New +$23 ﹤0.01% 6629
2020
Q1 		– Hold
0
– – – 6600
2019
Q4 		– Hold
0
– – – 6675
2019
Q3 		– Sell
-666
Closed -$9.58K – 6665
2019
Q2 		$12K Sell
666
-11
-2% -$481 ﹤0.01% 6080
2019
Q1 		$49K Buy
677
+665
+5,542% +$44.1K ﹤0.01% 5668
2018
Q4 		$0 Sell
12
-222
-95% -$14.2K ﹤0.01% 6623
2018
Q3 		$20K Buy
234
+106
+83% +$10.8K ﹤0.01% 6132
2018
Q2 		$16K Buy
+128
New +$13.2K ﹤0.01% 6197
2017
Q4 		– Sell
-2
Closed – – 6586
2017
Q3 		$0 Sell
2
-4
-67% -$332 ﹤0.01% 6548
2017
Q2 		$0 Sell
6
-81
-93% -$8.25K ﹤0.01% 6601
2017
Q1 		$12K Sell
87
-226
-72% -$33.2K ﹤0.01% 6194
2016
Q4 		$49K Buy
313
+268
+596% +$51.4K ﹤0.01% 5755
2016
Q3 		$11K Buy
45
+33
+275% +$12.1K ﹤0.01% 6089
2016
Q2 		$12K Buy
12
+6
+100% +$6.62K ﹤0.01% 6008
2016
Q1 		$5K Sell
6
-25
-81% -$24.5K ﹤0.01% 6278
2015
Q4 		$45K Buy
31
+4
+15% +$6.97K ﹤0.01% 5759
2015
Q3 		$45K Buy
27
+24
+800% +$49.4K ﹤0.01% 5773
2015
Q2 		$6K Sell
3
-21
-88% -$40.6K ﹤0.01% 6395
2015
Q1 		$44K Buy
24
+22
+1,100% +$48.5K ﹤0.01% 5843
2014
Q4 		$4K Sell
2
-961
-100% -$2.28M ﹤0.01% 6365
2014
Q3 		$2.36M Buy
+963
New +$2.74M ﹤0.01% 3292

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Morgan Stanley's ELDN Position: Q1 2026 in Review

Morgan Stanley reduced its Eledon Pharmaceuticals (ELDN) stake by 40% in Q1 2026, selling an estimated $225K and leaving 145,158 shares worth $447K. The position accounts for ﹤0.01% of the portfolio, ranked #5537.

Morgan Stanley first reported a position in ELDN in Q3 2014 and has held it in 40 quarters since. The position peaked at $6.73M in Q2 2021. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

  • Morgan Stanley held 145,158 shares of Eledon Pharmaceuticals worth $447K as of Q1 2026.
  • Morgan Stanley sold 95,387 Eledon Pharmaceuticals shares in Q1 2026, an estimated $225K.
  • Eledon Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5537 holding.
  • Morgan Stanley first reported a position in Eledon Pharmaceuticals in Q3 2014 and has held it in 40 quarters since.
  • Morgan Stanley's Eledon Pharmaceuticals position peaked at $6.73M in Q2 2021.
  • 121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.